Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Reblozyl (luspatercept by Year
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Reblozyl (luspatercept: 41.0% in FY2025, down 34.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Alliance Revenue – Reblozyl (3) | 119 | 107 | 136 | 164 | 525 | 71 | 90 | 100 | 110 | 371 | 48 | 48 | 41 | 41”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.0% | -34.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 75.0% | +47.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 28.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Reblozyl (luspatercept (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-reblozyl-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.